Cytokine-based Immuno-oncology
Undisclosed cancers
ResearchActive
Key Facts
About Sutro Biopharma
Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.
View full company profileTherapeutic Areas
Other Undisclosed cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Next-generation ADCs | Sutro Biopharma | Discovery/Preclinical |
| Bispecific Antibody Programs | Compugen | Preclinical |